康诺亚生物医药科技成都有限公司
CN
 
CN
About Us

● CMG901 for the treatment of gastric 

cancer and gastroesophageal junction

 adenocarcinoma was granted the 

Orphan-drug Designation by the FDA.

● FDA granted CMG901 Fast Track

 Designation for unresectable or metastatic

 gastric and gastroesophageal junction 

cancer which have relapsed and/or are 

refractory to approved therapies.